Acetohydroxamic acid
Clinical data | |
---|---|
AHFS/Drugs.com | Consumer Drug Information |
ATC code | G04BX03 (WHO) |
Identifiers | |
| |
CAS Number | 546-88-3 |
PubChem (CID) | 1990 |
DrugBank | DB00551 |
ChemSpider | 1913 |
UNII | 4RZ82L2GY5 |
KEGG | D00220 |
ChEBI | CHEBI:49029 |
ChEMBL | CHEMBL734 |
Chemical and physical data | |
Formula | C2H5NO2 |
Molar mass | 75.0666 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Acetohydroxamic acid (also known as AHA or Lithostat) is a drug that is a potent and irreversible inhibitor of bacterial and plant urease usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by the urease enzyme.[1]
Orphan drug
In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983.[2] AHA cannot be patented because it is a standard chemical compound.[2]
References
- ↑ W. Fishbein; P. Carbone (June 1965). "Urease catalysis. ii. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid". J Biol Chem. 240: 2407–14.
- 1 2 Marwick, Charles (1983). "New drugs selectively inhibit kidney stone formation". The Journal of the American Medical Association. 240 (3): 321–322. doi:10.1001/jama.1983.03340030003001.
See also
This article is issued from Wikipedia - version of the 9/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.